Clinical, Biological, and Anatomical Characteristics of the Patients at Baseline and After 6 Months of Treatment With Liraglutide
| Characteristic . | Values at Baseline . | Values After 6 Months of Liraglutide Treatment . | P . |
|---|---|---|---|
| Sex, M/F, no. | 37/31 | ||
| Age, mean ± SD, y | 56.9 ± 11.3 | ||
| Diabetes duration, mean ± SD, y | 11.0 ± 8.7 | ||
| Antidiabetic treatment, no. (%) | |||
| Metformin | 61 (90) | ||
| Sulfonylurea or glinide | 41 (60) | ||
| Insulin | 14 (21) | ||
| Body weight, mean ± SD, kg | 99.5 ± 19.6 | 95.9 ± 19.2 | <0.0001 |
| BMI, mean ± SD, kg/m2 | 35.9 ± 6.8 | 34.7 ± 6.8 | <0.0001 |
| HbA1c, mean ± SD, % | 9.8 ± 2.1 | 7.3 ± 1.1 | <0.0001 |
| ALT level, mean ± SD, UI/L | 45.9 ± 23.8 | 39.5 ± 16.6 | 0.021 |
| AST level, mean ± SD, UI/L | 25.0 ± 12.3 | 23.5 ± 10.9 | NS |
| GGT level, mean ± SD, UI/L | 70.8 ± 91.5 | 46.0 ± 30.7 | 0.017 |
| LDL-C level, mean ± SD, mmol/L | 2.57 ± 0.89 | 2.38 ± 0.85 | NS |
| HDL-C level, mean ± SD, mmol/L | 1.08 ± 0.33 | 1.20 ± 0.43 | 0.004 |
| Triglyceride level, mean ± SD, mmol/L | 2.46 ± 1.86 | 1.90 ± 1.35 | 0.004 |
| Adiponectin level, mean ± SD, μg/L | 3216 ± 2687 | 4272 ± 2398 | <0.0001 |
| Liver fat content, mean ± SD, % | 17.3 ± 10.9 | 11.9 ± 9.3 | <0.0001 |
| Visceral fat area, mean ± SD, cm2 | 254 ± 101 | 223 ± 105 | 0.005 |
| Subcutaneous fat area, mean ± SD, cm2 | 384 ± 160 | 358 ± 155 | 0.009 |
| Characteristic . | Values at Baseline . | Values After 6 Months of Liraglutide Treatment . | P . |
|---|---|---|---|
| Sex, M/F, no. | 37/31 | ||
| Age, mean ± SD, y | 56.9 ± 11.3 | ||
| Diabetes duration, mean ± SD, y | 11.0 ± 8.7 | ||
| Antidiabetic treatment, no. (%) | |||
| Metformin | 61 (90) | ||
| Sulfonylurea or glinide | 41 (60) | ||
| Insulin | 14 (21) | ||
| Body weight, mean ± SD, kg | 99.5 ± 19.6 | 95.9 ± 19.2 | <0.0001 |
| BMI, mean ± SD, kg/m2 | 35.9 ± 6.8 | 34.7 ± 6.8 | <0.0001 |
| HbA1c, mean ± SD, % | 9.8 ± 2.1 | 7.3 ± 1.1 | <0.0001 |
| ALT level, mean ± SD, UI/L | 45.9 ± 23.8 | 39.5 ± 16.6 | 0.021 |
| AST level, mean ± SD, UI/L | 25.0 ± 12.3 | 23.5 ± 10.9 | NS |
| GGT level, mean ± SD, UI/L | 70.8 ± 91.5 | 46.0 ± 30.7 | 0.017 |
| LDL-C level, mean ± SD, mmol/L | 2.57 ± 0.89 | 2.38 ± 0.85 | NS |
| HDL-C level, mean ± SD, mmol/L | 1.08 ± 0.33 | 1.20 ± 0.43 | 0.004 |
| Triglyceride level, mean ± SD, mmol/L | 2.46 ± 1.86 | 1.90 ± 1.35 | 0.004 |
| Adiponectin level, mean ± SD, μg/L | 3216 ± 2687 | 4272 ± 2398 | <0.0001 |
| Liver fat content, mean ± SD, % | 17.3 ± 10.9 | 11.9 ± 9.3 | <0.0001 |
| Visceral fat area, mean ± SD, cm2 | 254 ± 101 | 223 ± 105 | 0.005 |
| Subcutaneous fat area, mean ± SD, cm2 | 384 ± 160 | 358 ± 155 | 0.009 |
Abbreviation: NS, not significant.
Clinical, Biological, and Anatomical Characteristics of the Patients at Baseline and After 6 Months of Treatment With Liraglutide
| Characteristic . | Values at Baseline . | Values After 6 Months of Liraglutide Treatment . | P . |
|---|---|---|---|
| Sex, M/F, no. | 37/31 | ||
| Age, mean ± SD, y | 56.9 ± 11.3 | ||
| Diabetes duration, mean ± SD, y | 11.0 ± 8.7 | ||
| Antidiabetic treatment, no. (%) | |||
| Metformin | 61 (90) | ||
| Sulfonylurea or glinide | 41 (60) | ||
| Insulin | 14 (21) | ||
| Body weight, mean ± SD, kg | 99.5 ± 19.6 | 95.9 ± 19.2 | <0.0001 |
| BMI, mean ± SD, kg/m2 | 35.9 ± 6.8 | 34.7 ± 6.8 | <0.0001 |
| HbA1c, mean ± SD, % | 9.8 ± 2.1 | 7.3 ± 1.1 | <0.0001 |
| ALT level, mean ± SD, UI/L | 45.9 ± 23.8 | 39.5 ± 16.6 | 0.021 |
| AST level, mean ± SD, UI/L | 25.0 ± 12.3 | 23.5 ± 10.9 | NS |
| GGT level, mean ± SD, UI/L | 70.8 ± 91.5 | 46.0 ± 30.7 | 0.017 |
| LDL-C level, mean ± SD, mmol/L | 2.57 ± 0.89 | 2.38 ± 0.85 | NS |
| HDL-C level, mean ± SD, mmol/L | 1.08 ± 0.33 | 1.20 ± 0.43 | 0.004 |
| Triglyceride level, mean ± SD, mmol/L | 2.46 ± 1.86 | 1.90 ± 1.35 | 0.004 |
| Adiponectin level, mean ± SD, μg/L | 3216 ± 2687 | 4272 ± 2398 | <0.0001 |
| Liver fat content, mean ± SD, % | 17.3 ± 10.9 | 11.9 ± 9.3 | <0.0001 |
| Visceral fat area, mean ± SD, cm2 | 254 ± 101 | 223 ± 105 | 0.005 |
| Subcutaneous fat area, mean ± SD, cm2 | 384 ± 160 | 358 ± 155 | 0.009 |
| Characteristic . | Values at Baseline . | Values After 6 Months of Liraglutide Treatment . | P . |
|---|---|---|---|
| Sex, M/F, no. | 37/31 | ||
| Age, mean ± SD, y | 56.9 ± 11.3 | ||
| Diabetes duration, mean ± SD, y | 11.0 ± 8.7 | ||
| Antidiabetic treatment, no. (%) | |||
| Metformin | 61 (90) | ||
| Sulfonylurea or glinide | 41 (60) | ||
| Insulin | 14 (21) | ||
| Body weight, mean ± SD, kg | 99.5 ± 19.6 | 95.9 ± 19.2 | <0.0001 |
| BMI, mean ± SD, kg/m2 | 35.9 ± 6.8 | 34.7 ± 6.8 | <0.0001 |
| HbA1c, mean ± SD, % | 9.8 ± 2.1 | 7.3 ± 1.1 | <0.0001 |
| ALT level, mean ± SD, UI/L | 45.9 ± 23.8 | 39.5 ± 16.6 | 0.021 |
| AST level, mean ± SD, UI/L | 25.0 ± 12.3 | 23.5 ± 10.9 | NS |
| GGT level, mean ± SD, UI/L | 70.8 ± 91.5 | 46.0 ± 30.7 | 0.017 |
| LDL-C level, mean ± SD, mmol/L | 2.57 ± 0.89 | 2.38 ± 0.85 | NS |
| HDL-C level, mean ± SD, mmol/L | 1.08 ± 0.33 | 1.20 ± 0.43 | 0.004 |
| Triglyceride level, mean ± SD, mmol/L | 2.46 ± 1.86 | 1.90 ± 1.35 | 0.004 |
| Adiponectin level, mean ± SD, μg/L | 3216 ± 2687 | 4272 ± 2398 | <0.0001 |
| Liver fat content, mean ± SD, % | 17.3 ± 10.9 | 11.9 ± 9.3 | <0.0001 |
| Visceral fat area, mean ± SD, cm2 | 254 ± 101 | 223 ± 105 | 0.005 |
| Subcutaneous fat area, mean ± SD, cm2 | 384 ± 160 | 358 ± 155 | 0.009 |
Abbreviation: NS, not significant.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
